<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02069392</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00058233</org_study_id>
    <secondary_id>R21MH095824</secondary_id>
    <nct_id>NCT02069392</nct_id>
  </id_info>
  <brief_title>Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia</brief_title>
  <official_title>Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia is marked by problems in attention, memory and problem solving. These deficits
      predict long-term functional outcome such as the ability to live independently and maintain
      employment, but they are not ameliorated by currently available medications. Cognitive
      training improves these functions to some degree, but this approach is time- and
      resource-intensive. The current project aims at enhancing and accelerating the benefits that
      people with schizophrenia derive from cognitive training by administering nicotine during
      some of the training sessions. This would provide the proof of principle for a type of
      treatment intervention to improve cognitive symptoms of schizophrenia.

      The current project aims at determining whether the intermittent presence of nicotine during
      cognitive training exercises in people with schizophrenia will shorten the training period
      necessary to induce significant and clinically relevant improvement and enhance the
      improvement seen after a training period of specified length.

      Hypothesis 1a: Nicotine administration during training will increase the size of all measured
      effects of the training intervention, and will accelerate the time course of performance
      enhancement on the MCCB and training exercise progression parameters.

      Hypothesis 1b: The larger training effects in the Nicotine Group will persist beyond the end
      of the intervention.

      Hypothesis 2a: Within-session progress on the training exercises will be larger in the
      presence of nicotine than in the presence of placebo.

      Hypothesis 2b: These acute nicotine-induced performance elevations will persist beyond the
      presence of nicotine through subsequent non-drug training sessions, giving evidence of an
      acute facilitation of learning processes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MATRICS Consensus Cognitive Battery (MCCB) Composite Score</measure>
    <time_frame>baseline (week 0), weeks 4 and 7 of intervention, end-of-intervention (week 10), 4-week follow-up</time_frame>
    <description>The MCCB is an FDA-approved assessment tool for trials of cognition-enhancing treatments in people with schizophrenia. The MCCB is comprised of the following domains: 1) Speed of Processing; 2) Attention/Vigilance; 3) Working Memory; 4) Verbal Learning; 5) Visual Learning; 6) Reasoning and Problem Solving; and 7) Social Cognition. The composite score is standardized to a T-scale (mean=50, standard deviation=10) based on healthy control normative data. Better performance is reflected by higher scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive Assessment Interview (CAI) Score</measure>
    <time_frame>baseline (week 0) and post-intervention (week 10)</time_frame>
    <description>Clinician-administered interview about daily life cognitive functioning. The CAI assesses 10 items related to working memory, attention/vigilance, learning/memory, problem solving, processing speed, and social cognition. The total score ranges from 1 (inability to maintain personal hygiene due to cognitive deficits) to 100 (superior cognitive functioning in a wide range of activities). A score of 55 corresponds to moderate cognitive symptoms, e.g. persistent problems paying attention or forgetting scheduled events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Abbreviated Schizophrenia Quality of Life Scale Score</measure>
    <time_frame>baseline (week 0) and post-intervention (week 10)</time_frame>
    <description>Semi-structured clinician interview measuring functional outcome and quality of life in people with schizophrenia. Includes subjective questions regarding life satisfaction and objective indicators of social and occupational role functioning during preceding 4 weeks. Seven items are scored on a 0 (severe impairment) to 6 (high functioning) scale. The total score ranges from 0 to 42, with larger values reflecting higher functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UCSD Performance-Based Skills Assessment (UPSA) Score</measure>
    <time_frame>baseline (week 0) and post-intervention (week 10)</time_frame>
    <description>Measures ability to perform real-life tasks by standardized role-play. Scores reflect percent correct, i.e. range from 0-100 with higher scores representing better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calgary Depression Scale Score</measure>
    <time_frame>baseline (week 0), post-intervention (week 10)</time_frame>
    <description>Clinician scale developed to assess the level of depression in schizophrenia. 9 items assess symptoms of depression and overall rater impression on a scale from 0 (absent) to 3 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scale for the Assessment of Negative Symptoms (SANS) Score</measure>
    <time_frame>baseline (week 0), post-intervention (week 10)</time_frame>
    <description>Clinician rating scale of negative symptoms in schizophrenia. Within each of 5 domains, separate symptoms are rated from 0 (absent) to 5 (severe). Total scores are the sum of 22 subscales and range from 0 to 110, with larger values reflecting higher negative symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Psychiatric Rating Scale (BPRS) Score</measure>
    <time_frame>baseline (week 0), post-intervention (week 10)</time_frame>
    <description>Clinician rating scale to measure psychotic symptoms. Each of 20 items is scored 1-7. Total scores are the sum of all items and range from 20 to 140, with larger values reflecting worse symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Training Exercise Parameters: Visual and Sound Sweeps</measure>
    <time_frame>baseline (week 0), post-intervention (week 10), 4-week follow-up</time_frame>
    <description>Some of the Posit Science exercises provide an assessment tool of training progress on task parameters, which adjust continuously to keep performance at ~85% correct. Enhanced sensory processing speed and precision is considered the central building block of training benefits. Therefore, we analyzed the two exercises aimed at training these processes. Performance is quantified as stimulus presentation time in ms of visual or sound &quot;sweeps&quot;, which the participant has to judge in terms of change across space or time. Smaller values reflect better performance. Visual and sound sweeps were averaged.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Working Memory Capacity</measure>
    <time_frame>baseline (week 1) and post-intervention (week 10)</time_frame>
    <description>Derived from a computerized change localization task. One to four colored squares are shown for 100 ms. After a delay, they reappear and the task is to click on the one square that has changed color (50% chance). Performance is expressed as the percentage of correct responses.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Cognitive remediation training with nicotine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitive remediation training without nicotine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a placebo lozenge prior to the training.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive remediation training</intervention_name>
    <arm_group_label>Cognitive remediation training with nicotine</arm_group_label>
    <arm_group_label>Cognitive remediation training without nicotine</arm_group_label>
    <other_name>Posit Science cognitive remediation training</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine polacrilex lozenge</intervention_name>
    <description>Of interest are the effects of nicotine on cognitive remediation training benefits.</description>
    <arm_group_label>Cognitive remediation training with nicotine</arm_group_label>
    <other_name>Nicorette polacrilex lozenges, GlaxoSmithKline, 2 mg and 4 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18-60 years.

          -  DSM diagnosis of schizophrenia or schizoaffective disorder.

          -  Ability to give written informed consent.

          -  Either currently smoking and not attempting to quit, or having smoked no more than 80
             cigarettes, cigarillos or cigars in lifetime and not at all within the last year.

          -  Normal or corrected to normal vision (at least 20/50).

          -  Four weeks of stable pharmacological treatment (same psychiatric medication at same
             dose) and no foreseeable changes at enrollment.

        Exclusion Criteria:

          -  Alcohol or substance abuse or dependence other than nicotine within the last 12
             months.

          -  Uncontrolled hypertension (resting systolic blood pressure above 150 or diastolic
             above 90 mm Hg).

          -  History of myocardial infarction, heart failure, angina, stroke or severe arrhythmias.

          -  ECG abnormalities.

          -  History of neurological conditions such as stroke, seizures, dementia or organic brain
             syndrome.

          -  Mental retardation.

          -  Pregnant, verified by urine pregnancy test for females.

          -  Breast-feeding.

          -  Treated with benztropine currently or within the last four weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Britta Hahn, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland School of Medicine, Maryland Psychiatric Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maryland Psychiatric Research Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 5, 2014</study_first_submitted>
  <study_first_submitted_qc>February 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2014</study_first_posted>
  <results_first_submitted>November 12, 2018</results_first_submitted>
  <results_first_submitted_qc>April 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2019</results_first_posted>
  <last_update_submitted>September 10, 2019</last_update_submitted>
  <last_update_submitted_qc>September 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Britta Hahn</investigator_full_name>
    <investigator_title>Associate Professor (Britta Hahn, Ph.D.)</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>cognition</keyword>
  <keyword>cognitive remediation</keyword>
  <keyword>nicotine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT02069392/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cognitive Remediation Training With Nicotine</title>
          <description>Participants complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
Cognitive remediation training
Nicotine polacrilex lozenge: Of interest are the effects of nicotine on cognitive remediation training benefits.</description>
        </group>
        <group group_id="P2">
          <title>Cognitive Remediation Training Without Nicotine</title>
          <description>Participants complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a placebo lozenge prior to the training.
Cognitive remediation training</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cognitive Remediation Training With Nicotine</title>
          <description>Participants complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
Cognitive remediation training
Nicotine polacrilex lozenge: Of interest are the effects of nicotine on cognitive remediation training benefits.</description>
        </group>
        <group group_id="B2">
          <title>Cognitive Remediation Training Without Nicotine</title>
          <description>Participants complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a placebo lozenge prior to the training.
Cognitive remediation training</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.0" spread="11.0"/>
                    <measurement group_id="B2" value="43.8" spread="12.0"/>
                    <measurement group_id="B3" value="43.5" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Smokers</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MATRICS Consensus Cognitive Battery (MCCB) Composite Score</title>
        <description>The MCCB is an FDA-approved assessment tool for trials of cognition-enhancing treatments in people with schizophrenia. The MCCB is comprised of the following domains: 1) Speed of Processing; 2) Attention/Vigilance; 3) Working Memory; 4) Verbal Learning; 5) Visual Learning; 6) Reasoning and Problem Solving; and 7) Social Cognition. The composite score is standardized to a T-scale (mean=50, standard deviation=10) based on healthy control normative data. Better performance is reflected by higher scores.</description>
        <time_frame>baseline (week 0), weeks 4 and 7 of intervention, end-of-intervention (week 10), 4-week follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Remediation Training With Nicotine</title>
            <description>Participants complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
Cognitive remediation training
Nicotine polacrilex lozenge: Of interest are the effects of nicotine on cognitive remediation training benefits.</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Remediation Training Without Nicotine</title>
            <description>Participants complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a placebo lozenge prior to the training.
Cognitive remediation training</description>
          </group>
        </group_list>
        <measure>
          <title>MATRICS Consensus Cognitive Battery (MCCB) Composite Score</title>
          <description>The MCCB is an FDA-approved assessment tool for trials of cognition-enhancing treatments in people with schizophrenia. The MCCB is comprised of the following domains: 1) Speed of Processing; 2) Attention/Vigilance; 3) Working Memory; 4) Verbal Learning; 5) Visual Learning; 6) Reasoning and Problem Solving; and 7) Social Cognition. The composite score is standardized to a T-scale (mean=50, standard deviation=10) based on healthy control normative data. Better performance is reflected by higher scores.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.30" spread="15.42"/>
                    <measurement group_id="O2" value="33.87" spread="10.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.50" spread="14.98"/>
                    <measurement group_id="O2" value="35.47" spread="9.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.30" spread="13.70"/>
                    <measurement group_id="O2" value="36.87" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (end of intervention)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.60" spread="14.38"/>
                    <measurement group_id="O2" value="36.67" spread="10.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-week follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.00" spread="12.67"/>
                    <measurement group_id="O2" value="37.87" spread="10.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Assessment Interview (CAI) Score</title>
        <description>Clinician-administered interview about daily life cognitive functioning. The CAI assesses 10 items related to working memory, attention/vigilance, learning/memory, problem solving, processing speed, and social cognition. The total score ranges from 1 (inability to maintain personal hygiene due to cognitive deficits) to 100 (superior cognitive functioning in a wide range of activities). A score of 55 corresponds to moderate cognitive symptoms, e.g. persistent problems paying attention or forgetting scheduled events.</description>
        <time_frame>baseline (week 0) and post-intervention (week 10)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Remediation Training With Nicotine</title>
            <description>Participants complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
Cognitive remediation training
Nicotine polacrilex lozenge: Of interest are the effects of nicotine on cognitive remediation training benefits.</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Remediation Training Without Nicotine</title>
            <description>Participants complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a placebo lozenge prior to the training.
Cognitive remediation training</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Assessment Interview (CAI) Score</title>
          <description>Clinician-administered interview about daily life cognitive functioning. The CAI assesses 10 items related to working memory, attention/vigilance, learning/memory, problem solving, processing speed, and social cognition. The total score ranges from 1 (inability to maintain personal hygiene due to cognitive deficits) to 100 (superior cognitive functioning in a wide range of activities). A score of 55 corresponds to moderate cognitive symptoms, e.g. persistent problems paying attention or forgetting scheduled events.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.80" spread="12.88"/>
                    <measurement group_id="O2" value="59.14" spread="9.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-intervention (week 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.30" spread="12.52"/>
                    <measurement group_id="O2" value="64.79" spread="10.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Abbreviated Schizophrenia Quality of Life Scale Score</title>
        <description>Semi-structured clinician interview measuring functional outcome and quality of life in people with schizophrenia. Includes subjective questions regarding life satisfaction and objective indicators of social and occupational role functioning during preceding 4 weeks. Seven items are scored on a 0 (severe impairment) to 6 (high functioning) scale. The total score ranges from 0 to 42, with larger values reflecting higher functioning.</description>
        <time_frame>baseline (week 0) and post-intervention (week 10)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Remediation Training With Nicotine</title>
            <description>Participants complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
Cognitive remediation training
Nicotine polacrilex lozenge: Of interest are the effects of nicotine on cognitive remediation training benefits.</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Remediation Training Without Nicotine</title>
            <description>Participants complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a placebo lozenge prior to the training.
Cognitive remediation training</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Abbreviated Schizophrenia Quality of Life Scale Score</title>
          <description>Semi-structured clinician interview measuring functional outcome and quality of life in people with schizophrenia. Includes subjective questions regarding life satisfaction and objective indicators of social and occupational role functioning during preceding 4 weeks. Seven items are scored on a 0 (severe impairment) to 6 (high functioning) scale. The total score ranges from 0 to 42, with larger values reflecting higher functioning.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.30" spread="5.70"/>
                    <measurement group_id="O2" value="20.29" spread="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-intervention (week 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.90" spread="5.88"/>
                    <measurement group_id="O2" value="23.00" spread="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>UCSD Performance-Based Skills Assessment (UPSA) Score</title>
        <description>Measures ability to perform real-life tasks by standardized role-play. Scores reflect percent correct, i.e. range from 0-100 with higher scores representing better performance.</description>
        <time_frame>baseline (week 0) and post-intervention (week 10)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Remediation Training With Nicotine</title>
            <description>Participants complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
Cognitive remediation training
Nicotine polacrilex lozenge: Of interest are the effects of nicotine on cognitive remediation training benefits.</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Remediation Training Without Nicotine</title>
            <description>Participants complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a placebo lozenge prior to the training.
Cognitive remediation training</description>
          </group>
        </group_list>
        <measure>
          <title>UCSD Performance-Based Skills Assessment (UPSA) Score</title>
          <description>Measures ability to perform real-life tasks by standardized role-play. Scores reflect percent correct, i.e. range from 0-100 with higher scores representing better performance.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.50" spread="14.97"/>
                    <measurement group_id="O2" value="71.87" spread="14.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-intervention (week 10_</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.50" spread="14.55"/>
                    <measurement group_id="O2" value="74.00" spread="12.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Calgary Depression Scale Score</title>
        <description>Clinician scale developed to assess the level of depression in schizophrenia. 9 items assess symptoms of depression and overall rater impression on a scale from 0 (absent) to 3 (severe).</description>
        <time_frame>baseline (week 0), post-intervention (week 10)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Remediation Training With Nicotine</title>
            <description>Participants complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
Cognitive remediation training
Nicotine polacrilex lozenge: Of interest are the effects of nicotine on cognitive remediation training benefits.</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Remediation Training Without Nicotine</title>
            <description>Participants complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a placebo lozenge prior to the training.
Cognitive remediation training</description>
          </group>
        </group_list>
        <measure>
          <title>Calgary Depression Scale Score</title>
          <description>Clinician scale developed to assess the level of depression in schizophrenia. 9 items assess symptoms of depression and overall rater impression on a scale from 0 (absent) to 3 (severe).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="2.45"/>
                    <measurement group_id="O2" value="2.07" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-intervention (10 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" spread="2.59"/>
                    <measurement group_id="O2" value="1.40" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Scale for the Assessment of Negative Symptoms (SANS) Score</title>
        <description>Clinician rating scale of negative symptoms in schizophrenia. Within each of 5 domains, separate symptoms are rated from 0 (absent) to 5 (severe). Total scores are the sum of 22 subscales and range from 0 to 110, with larger values reflecting higher negative symptoms.</description>
        <time_frame>baseline (week 0), post-intervention (week 10)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Remediation Training With Nicotine</title>
            <description>Participants complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
Cognitive remediation training
Nicotine polacrilex lozenge: Of interest are the effects of nicotine on cognitive remediation training benefits.</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Remediation Training Without Nicotine</title>
            <description>Participants complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a placebo lozenge prior to the training.
Cognitive remediation training</description>
          </group>
        </group_list>
        <measure>
          <title>Scale for the Assessment of Negative Symptoms (SANS) Score</title>
          <description>Clinician rating scale of negative symptoms in schizophrenia. Within each of 5 domains, separate symptoms are rated from 0 (absent) to 5 (severe). Total scores are the sum of 22 subscales and range from 0 to 110, with larger values reflecting higher negative symptoms.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.40" spread="11.64"/>
                    <measurement group_id="O2" value="37.73" spread="7.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-intervention (10 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.80" spread="12.14"/>
                    <measurement group_id="O2" value="36.53" spread="7.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Psychiatric Rating Scale (BPRS) Score</title>
        <description>Clinician rating scale to measure psychotic symptoms. Each of 20 items is scored 1-7. Total scores are the sum of all items and range from 20 to 140, with larger values reflecting worse symptoms.</description>
        <time_frame>baseline (week 0), post-intervention (week 10)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Remediation Training With Nicotine</title>
            <description>Participants complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
Cognitive remediation training
Nicotine polacrilex lozenge: Of interest are the effects of nicotine on cognitive remediation training benefits.</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Remediation Training Without Nicotine</title>
            <description>Participants complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a placebo lozenge prior to the training.
Cognitive remediation training</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Psychiatric Rating Scale (BPRS) Score</title>
          <description>Clinician rating scale to measure psychotic symptoms. Each of 20 items is scored 1-7. Total scores are the sum of all items and range from 20 to 140, with larger values reflecting worse symptoms.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.40" spread="9.14"/>
                    <measurement group_id="O2" value="37.33" spread="7.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-intervention (10 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.50" spread="9.43"/>
                    <measurement group_id="O2" value="36.53" spread="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Training Exercise Parameters: Visual and Sound Sweeps</title>
        <description>Some of the Posit Science exercises provide an assessment tool of training progress on task parameters, which adjust continuously to keep performance at ~85% correct. Enhanced sensory processing speed and precision is considered the central building block of training benefits. Therefore, we analyzed the two exercises aimed at training these processes. Performance is quantified as stimulus presentation time in ms of visual or sound &quot;sweeps&quot;, which the participant has to judge in terms of change across space or time. Smaller values reflect better performance. Visual and sound sweeps were averaged.</description>
        <time_frame>baseline (week 0), post-intervention (week 10), 4-week follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Remediation Training With Nicotine</title>
            <description>Participants will complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
Cognitive remediation training
Nicotine polacrilex lozenge: Of interest are the effects of nicotine on cognitive remediation training benefits.</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Remediation Training Without Nicotine</title>
            <description>Participants will complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants will consume a placebo lozenge prior to the training.
Cognitive remediation training</description>
          </group>
        </group_list>
        <measure>
          <title>Training Exercise Parameters: Visual and Sound Sweeps</title>
          <description>Some of the Posit Science exercises provide an assessment tool of training progress on task parameters, which adjust continuously to keep performance at ~85% correct. Enhanced sensory processing speed and precision is considered the central building block of training benefits. Therefore, we analyzed the two exercises aimed at training these processes. Performance is quantified as stimulus presentation time in ms of visual or sound &quot;sweeps&quot;, which the participant has to judge in terms of change across space or time. Smaller values reflect better performance. Visual and sound sweeps were averaged.</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.25" spread="46.26"/>
                    <measurement group_id="O2" value="198.80" spread="159.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10 (end-of-treatment)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.40" spread="28.04"/>
                    <measurement group_id="O2" value="124.40" spread="73.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-week follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.80" spread="39.45"/>
                    <measurement group_id="O2" value="117.50" spread="69.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Working Memory Capacity</title>
        <description>Derived from a computerized change localization task. One to four colored squares are shown for 100 ms. After a delay, they reappear and the task is to click on the one square that has changed color (50% chance). Performance is expressed as the percentage of correct responses.</description>
        <time_frame>baseline (week 1) and post-intervention (week 10)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Remediation Training With Nicotine</title>
            <description>Participants complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
Cognitive remediation training
Nicotine polacrilex lozenge: Of interest are the effects of nicotine on cognitive remediation training benefits.</description>
          </group>
          <group group_id="O2">
            <title>Cognitive Remediation Training Without Nicotine</title>
            <description>Participants complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a placebo lozenge prior to the training.
Cognitive remediation training</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Working Memory Capacity</title>
          <description>Derived from a computerized change localization task. One to four colored squares are shown for 100 ms. After a delay, they reappear and the task is to click on the one square that has changed color (50% chance). Performance is expressed as the percentage of correct responses.</description>
          <units>percentage correct responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.7" spread="16.0"/>
                    <measurement group_id="O2" value="67.5" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-intervention (10 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.2" spread="13.7"/>
                    <measurement group_id="O2" value="68.6" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over the 10 weeks of exposure to cognitive remediation training with bi-weekly exposure to nicotine or placebo.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cognitive Remediation Training With Nicotine</title>
          <description>Participants complete daily sessions of Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a 2 mg (for non-smokers) or 4 mg (for smokers) nicotine polacrilex lozenge prior to the training.
Cognitive remediation training
Nicotine polacrilex lozenge: Of interest are the effects of nicotine on cognitive remediation training benefits.</description>
        </group>
        <group group_id="E2">
          <title>Cognitive Remediation Training Without Nicotine</title>
          <description>Participants complete daily Posit Science cognitive remediation training for 10 weeks. Twice a week, participants consume a placebo lozenge prior to the training.
Cognitive remediation training</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Britta Hahn, Ph.D.</name_or_title>
      <organization>University of Maryland School of Medicine</organization>
      <phone>4104026112</phone>
      <email>bhahn@som.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

